The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.
Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD.
Weidhaas JB, et al. Among authors: paulus r.
Cancer Res Commun. 2023 Oct 11;3(10):2074-2081. doi: 10.1158/2767-9764.CRC-23-0084.
Cancer Res Commun. 2023.
PMID: 37728512
Free PMC article.